Biogen Idec ( BIIB ) Q3 2014 Results - Earnings Call Webcast
Oct 22 (Reuters) - Biogen Idec Inc on Wednesday reported much higher-than-expected third-quarter profit and the company raised its full-year earnings forecast, even as its big-selling new oral...
Oct 22 (Reuters) - Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall...
Determining Biogen 's Fair Value
Forward Pharma's Threat To Biogen Idec 's Tecfidera
we have #10 seeded Biogen Idec Inc . (NASDAQ: BIIB ) taking on #7 seeded ..... Inc. (NYSE: ECL ). Biogen is a biotechnology company ..... Revenue ($ in billions) BIIB 23Jul14 3.49 2.84 ..... 1.02 3.57 3.55 Biogen is up 36.12% in the
Biogen Idec ( BIIB +0.1% ) will report Q3 results before the open on October 22. The conference call will start at 9:00 am ET. Consensus view is EPS of $3.45 on revenues of $2.5B. Post your comment!
Asset Management and Research : Biogen Idec BIIB reported strong second quarter ..... revisions and growth estimates, Biogen Idec still offers investors strong upside potential. About The Company Biogen Idec discovers, develops, manufactures
By Arie Goren : Biogen Idec Inc . (NASDAQ: BIIB ) will continue to benefit ..... Nevertheless, in my opinion, BIIB 's stock still has room to move up. Biogen has decent valuation ..... margin. The Company Biogen Idec is one of the world's
of large, powerful bio-pharmas. The others are Gilead (NASDAQ: GILD ), Regeneron (NASDAQ: REGN ) and Biogen Idec (NASDAQ: BIIB ). Management is deep and well-respected. Chairman / CEO Robert Hugin has executive experience within the